|Chelsea Therapeutics to accelerate new drug application for NORTHERA|
|Monday, 20 December 2010 07:38|
Chelsea Therapeutics (Nasdaq:CHTP) has scheduled a conference call to discuss the outcome of its recent FDA discussions and updated NDA filing strategy with investors today, December 20, 2010, at 9:00 AM Eastern Time. This morning, the company announced that it has completed a pre-NDA assessment with the U.S. Food and Drug Administration (FDA) and intends to accelerate its new drug application (NDA) for NORTHERA (droxidopa) for the treatment of symptomatic, neurogenic orthostatic hypotension (NOH), a chronic and potentially debilitating drop in blood pressure upon standing commonly associated Parkinson's disease, multiple system atrophy and pure autonomic failure.
At the meeting, the FDA agreed that the proposed NDA for Northera could be submitted based on combined data from Chelsea's two completed Phase III studies in NOH, Study 301 and Study 302, without the need for any further efficacy studies. During the meeting, the agency did request and Chelsea agreed to supply top-line results from a QTc study at the time of the 90-day Safety Update and conduct a post-marketing study to evaluate the clinical pharmacology of Northera in renally impaired patients.
Interested investors may participate in the conference call by dialing 877-638-9567 (domestic) or 720-545-0009 (international). A replay will be available for one week following the call by dialing 800-642-1687 for domestic participants or 706-645-9291 for international participants and entering passcode 33483444 when prompted.
Participants may also access both the live and archived webcast of the conference call on Chelsea's web site at www.chelseatherapeutics.com.